Amarin says board ‘ready’ to unlock true potential of VASCEPA/VAZKEPA

Amarin Corporation released the following statement: "Since joining the company two weeks ago, the new Amarin board has rolled up its sleeves and begun the hard work of creating value for shareholders.We continue to believe that Amarin has tremendous potential. Our drug has the potential to both improve cardiovascular outcomes for patients and create significant savings for payors – a unique proposition for a drug. Unfortunately for society, in our view, not enough patients worldwide are taking VASCEPA. Although the new board has begun its work with urgency, we appreciate that Rome was not built in a day. The work to be done is substantial. We will proceed diligently and thoughtfully as shareholders deserve our best efforts. To the hard-working employees at the company, we understand that any change, in this case a new board, can create uncertainty. We want employees to rest assured that we intend to create a great culture of success at Amarin where employees have the tools to succeed and are rewarded for their performance. We remain confident in our ability to leverage VASCEPA’s clinically important drug profile to unlock tremendous value for shareholders. With shareholders on the board, we believe Amarin’s best days are ahead."